Bio-Techne
NASDAQ: TECH
Stock price
72.45 USD
(-39.58%) 5 years
Financial Performance
5Y price score: (51)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 172.7%
%
ㅤ
By default your notes are visible only to you.
43.2
52-week range
72.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.3 %
Dividend Yield TTM
0.4 %
Market cap $
$ 11,343
Price / Earnings TTM
62.5
Price / Book TTM
5.4
PEG TTM
0.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
20.2 %
(38.2) %
172.7 %
Free cash flow per share growth
(7.6) %
(11.8) %
97.1 %
Earnings per share growth
427.3 %
33.3 %
65.7 %
Founded: 1,976
Employees: 3,100
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q3 (May 6, 2026)
1) Strategy & Leadership - Bio-Techne is focusing on operational discipline amidst a dynamic market environment. - The company is streamlining its brand portfolio from 10 brands to 3, enhancing customer engagement across research to clinical applications. - The leadership team is optimistic about fiscal 2027, citing encouraging indicators in U.S. academia and emerging biotech recovery.
2) Financial & Segment Results - Q3 total revenue was $311.4 million, down 2% YoY; organic revenue declined 2%, but underlying growth was 2% after adjusting for specific headwinds. - Adjusted EPS was $0.53, down $0.03 YoY; GAAP EPS improved to $0.32 from $0.14. - Segment performance: - Protein Sciences: Revenue declined 4% organically, but grew nearly 50% YoY when excluding cell therapy customer impacts. - Diagnostics & Spatial Biology: Achieved 3% organic growth, with COMET platform growing over 65%.
3) Problems / Headwinds - Emerging biotech spending continues to decline, with a high single-digit drop in revenues, reflecting a lag in spending following funding constraints from 2025. - Order timing issues related to cell therapy customers created a 400 basis point headwind in Q3. - The company anticipates flat organic growth in Q4, primarily due to ongoing challenges in the biotech sector.
4) Operational or Product Plans - Bio-Techne is leveraging AI to enhance protein design and improve operational efficiency. - The company is focused on expanding its Spatial Biology and Proteomic Analysis platforms, with strong growth expected in these areas. - Continued investment in cell therapy and diagnostics is planned, with a focus on maintaining high profitability.
5) Guidance & Outlook / Investor Angle - The company expects low single-digit underlying growth in Q4, with a more optimistic outlook for fiscal 2027 as funding conditions improve. - The anticipated recovery in biotech spending is expected to materialize in the first half of fiscal 2027, driven by increased funding and easing headwinds. - The leadership remains confident in the company’s ability to achieve mid-single-digit growth in fiscal 2027, supported by strong positions in core segments.
Bottom line: Bio-Techne is navigating a challenging market landscape but is well-positioned for recovery in fiscal 2027, with strong growth in key segments and a focus on operational efficiency. Investors can expect gradual improvement as funding conditions stabilize and customer spending increases.
Annual Reports, Presentations And IR Contacts
Go to the websiteBio-Techne — Financial Overview, Stock Price, Market Cap
Bio-Techne is a company. Founded in 1976. As of October 9, 2026, the company's market capitalization is $11343424050 with a current stock price of $72.45.